S103: TRIAL IN PROGRESS: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT-4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE. (31st January 2022) - Lal, A.; Brown, C.; Coates, T.; Kalfa, T.; Kwiatkowski, J.L.; Brevard, J.; Trenor, C.; Wood, K.; Sheth, S.